| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c4322cb4de342be2dbedcbe0c278f6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68123a3b6983aff3d4dfdfe0d3a1d191 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f22634aeae9830ea6b8931d34e44b41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7156e523743c0f1c26b9c8a8ccc47abb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_523babe81aa84eabde70e90430e932fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18690e9531286715808aee1807154954 |
| publicationDate |
2008-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20080091427-A |
| titleOfInvention |
Concurrent Chemotherapy and Immunotherapy |
| abstract |
Simultaneous application of chemotherapy and immunotherapy was considered contradictory because of the fear that chemotherapy-induced lymphopenia will eliminate the therapeutic efficacy of immunotherapy. Temozolomide has proven to be an effective chemotherapeutic agent for malignant glioma patients, and it is controversial to discontinue this agent from glioblastoma (GBM) patients for treatment with immunotherapy. Despite the conventional dogma, we demonstrate that chemotherapy and immunotherapy can be applied simultaneously without negating the effects of immunotherapy. Indeed, lymphopenia induced by temozolomide can synergize with peptide vaccines. |
| priorityDate |
2005-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |